Endocrinology

Top Story

Coadministration of phentermine, lorcaserin increases weight loss, not adverse events in adults with obesity

April 27, 2017

Adults with obesity assigned combination phentermine and lorcaserin therapy for 12 weeks saw greater weight loss compared with either agent alone, without an increase in potentially serotonergic adverse events, according to findings from a pilot safety study published in Obesity.

“In clinical studies, coadministration of serotonergic and noradrenergic drugs has led to additive weight loss,” Steven R. Smith, MD, chief scientific officer of Florida Hospital Research Services and scientific director at the Translational Research Institute for Metabolism and Diabetes at the Sanford Burnham Prebys Medical Discovery Institute, and colleagues wrote. “However, phentermine may be associated with increased serotonergic activity. Lorcaserin is a serotonergic agent; therefore, coadministration with phentermine could theoretically result in serotonergic events, adversely impacting safety.”

FDA News

FDA: Long-term safety, efficacy data added to Saxenda product label

April 27, 2017
The FDA today approved an updated product label for liraglutide injection 3 mg to include long-term safety and efficacy data from the 3-year SCALE Obesity and…
In the Journals Plus

Obesity, central obesity increase precocious puberty risk

April 27, 2017
The risk for precocious puberty may be increased with childhood obesity and/or central obesity; the risk is more pronounced in girls than boys, according to findings…
In the Journals Plus

VTE in women may suggest inappropriate prescriptions of combined hormonal contraceptives

April 26, 2017
Women assigned combined hormonal contraceptives who experience a venous thromboembolism may have vascular contraindications suggesting inappropriate prescriptions…
In the Journals Plus

Type 2 diabetes increases risk for dementia conversion in patients with mild cognitive impairment

April 26, 2017
Adults with type 1 diabetes and mild cognitive impairment are twice as likely to develop dementia as those who have mild cognitive impairment without diabetes, according…
More News Headlines »
CME

Improving Bone Strength and Reducing Fracture Risk in Osteoporosis

This activity is supported by an educational grant from Merck & Co., Inc.

Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue leading to reduced…
More »
Video
Meeting News

VIDEO: Bone screens still necessary in type 2 diabetes despite normal, high BMD

April 3, 2017
More »
Featured
The Endocrine Society Annual Meeting

The Endocrine Society Annual Meeting

CME CNE CE CE

Diabetic Retinopathy: Preferred Practice Patterns in Screening and Management

This activity is supported by an educational grant from Regeneron.

Diabetic retinopathy (DR) is a major cause of blindness among American adults aged 40 years and older. The prevalence…
More »
Current Issues
View the Current Issues
Advertisement
Advertisement